Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study
Articles
[키워드] Admission
Against
age
analysed
antimicrobial
available data
Bacterial infection
bloodstream
carbapenem
case report form
caused
CCP-UK
characterisation
clinical
clinically
Co-infection
collected
Community
concerning
conducted
Critical care
Culture
demographic
Department
development
diagnosed
eligible
England
Enterobacteriaceae
Escherichia coli
European
excluded
female
finding
for inclusion
foundation
Frequency
funding
Haemophilus influenzae
highest
hospital
Hospital admission
hospitalised
Imperial College London
Infection
Inpatient
Intervention
IQR
ISARIC
ISARIC WHO CCP-UK
Laboratory
likelihood
median
Medical Research Council
Melinda Gate
microbiologically
multicentre
NIHR
NIHR HPRU
organism
outcome
pandemic
pathogen
Pathogens
Patient
patients
patients with COVID-19
predominant
prospective cohort study
protection
recorded
respiratory
SARS-COV-2 infection
SARS-CoV-2 test
Secondary infection
secondary infections
secondary respiratory infections
Staphylococcus aureus
target
therapeutic
unit
University of Liverpool
Wellcome Trust
were excluded
were recorded
WHO
with COVID-19
[DOI] 10.1016/S2666-5247(21)00090-2 PMC 바로가기 [Article Type] Articles
[DOI] 10.1016/S2666-5247(21)00090-2 PMC 바로가기 [Article Type] Articles